Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

Phase 1 Unknown 22 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd. Bristol-Myers Squibb · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to assess the single dose PK, safety, tolerability and immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.

Timeline

Start: 2016-10
Primary completion: 2017-02
Completion: 2017-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	125 mg	Subcutaneous

Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously

Summary

Timeline

Drugs

Indications